Recombinant
RabMAb

Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876)

Overview

  • Product name
    Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y]
    See all Caveolin-1 primary antibodies
  • Description
    Rabbit monoclonal [EPR2288Y] to Caveolin-1 (phospho Y14)
  • Specificity
    ab75876 detects Caveolin-1 phosphorylated at tyrosine 14.
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Caveolin-1.
    Database link: Q03135

  • Positive control
    • WB: A673, Insulin treated A673, A673 treated with insulin then the membrane was incubated with phosphatase, HeLa and HeLa cell treated with pervanadate whole cell lysate.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    A trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab75876 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000 - 1/5000. Predicted molecular weight: 20 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function
      May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway.
    • Tissue specificity
      Expressed in muscle and lung, less so in liver, brain and kidney.
    • Involvement in disease
      Defects in CAV1 are the cause of congenital generalized lipodystrophy type 3 (CGL3) [MIM:612526]; also called Berardinelli-Seip congenital lipodystrophy type 3 (BSCL3). Congenital generalized lipodystrophies are autosomal recessive disorders characterized by a near absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes.
    • Sequence similarities
      Belongs to the caveolin family.
    • Post-translational
      modifications
      The initiator methionine for isoform Beta is removed during or just after translation. The new N-terminal amino acid is then N-acetylated.
    • Cellular localization
      Golgi apparatus membrane. Cell membrane. Membrane > caveola. Membrane raft. Colocalized with DPP4 in membrane rafts. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
    • Information by UniProt
    • Database links
    • Alternative names
      • BSCL3 antibody
      • CAV antibody
      • CAV1 antibody
      • CAV1_HUMAN antibody
      • caveolae protein, 22 kD antibody
      • caveolin 1 alpha isoform antibody
      • caveolin 1 beta isoform antibody
      • Caveolin 1 caveolae protein 22kDa antibody
      • Caveolin-1 antibody
      • Caveolin1 antibody
      • cell growth-inhibiting protein 32 antibody
      • CGL3 antibody
      • LCCNS antibody
      • MSTP085 antibody
      • OTTHUMP00000025031 antibody
      • PPH3 antibody
      • VIP 21 antibody
      • VIP21 antibody
      see all

    Images

    • All lanes : Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876) at 1/1000 dilution

      Lane 1 : Untreated A673 (Human muscle Ewing's Sarcoma) whole cell lysates
      Lane 2 : A673 (Human muscle Ewing's Sarcoma) treated with insulin, whole cell lysates
      Lane 3 : A673 (Human muscle Ewing's Sarcoma) treated with insulin, whole cell lysates. Then the membrane was incubated with phosphatase.

      Lysates/proteins at 15 µg per lane.

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size : 20 kDa


      Exposure time : 30 seconds

      Blocking/Diluting buffer 5% NFDM/TBST

    • All lanes : Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876) at 1/2000 dilution

      Lane 1 : HeLa cell lysate
      Lane 2 : HeLa cell lysate treated with pervanadate

      Lysates/proteins at 10 µg per lane.

      Secondary
      Goat anti-rabbit HRP at 1/1000 dilution

      Predicted band size : 20 kDa
      Observed band size : 22 kDa (why is the actual band size different from the predicted?)
    • Dot blot analysis of Caveolin-1 (phospho Y14) phospho peptide (Lane 1), Caveolin-1 Non-phospho peptide (Lane 2) labelling Caveolin-1 (phospho Y14) with ab75876 at a dilution of 1/1000. Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/2500.

      Blocking and diluting buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    References

    ab75876 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab75876.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up